Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:China
|
| gptkbp:ATCCode |
L01FF13
|
| gptkbp:brand |
Cejemly
|
| gptkbp:CASNumber |
2135637-60-2
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
gptkb:CStone_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sugemalimab
|
| gptkbp:indication |
gptkb:stage_III_non-small_cell_lung_cancer
gptkb:stage_IV_non-small_cell_lung_cancer |
| gptkbp:macromoleculeType |
IgG4 monoclonal antibody
|
| gptkbp:mechanismOfAction |
immunotherapy
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:target |
PD-L1
|
| gptkbp:UNII |
6Q1K6Q1Q1F
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
immunotherapy |
| gptkbp:bfsParent |
gptkb:CStone_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|